JP Morgan Maintains Overweight on Olema Pharmaceuticals, Raises Price Target to $58

Benzinga Newsdesk www.benzinga.com Positive 77.4%

Neg 0% Neu 0% Pos 77.4%

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and raises the price target from $55 to $58.